Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5UR | ISIN: US2267181046 | Ticker-Symbol: CI5A
Tradegate
20.01.25
21:49 Uhr
36,600 Euro
+0,200
+0,55 %
Branche
Internet
Aktienmarkt
Sonstige
1-Jahres-Chart
CRITEO SA ADR Chart 1 Jahr
5-Tage-Chart
CRITEO SA ADR 5-Tage-Chart
RealtimeGeldBriefZeit
36,00036,60020.01.
36,00036,60020.01.
PR Newswire
122 Leser
Artikel bewerten:
(0)

Criteo S.A.: Criteo Appoints Michael Komasinski as Chief Executive Officer

Finanznachrichten News

Komasinski brings over 20 years of experience in AdTech leading large global organizations and a proven track record of driving accelerated growth and scale

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO), the commerce media company, today announced that its Board of Directors appointed Michael Komasinski as Chief Executive Officer and a member of the Board, effective February 15, 2025. Komasinski will succeed Megan Clarken who, as previously announced, is retiring and will be stepping down from her role as CEO and from the Board. Clarken will serve in a senior advisory role to ensure a smooth transition.

"We ran a comprehensive search process to identify the next CEO of Criteo to ensure we have the right leader to spearhead the next phase of the Company's AI-fueled transformation and vision as the world's leading Commerce Media Platform," said Rachel Picard, Chair of Criteo's Board of Directors. "We are thrilled that Michael is joining us to lead Criteo at this exciting time in our journey. Michael is a high-caliber executive with the ideal mix of skills, including tech-enabled product development expertise, hands-on experience managing brand and retailer relationships, and a proven ability to drive accelerated growth and scale globally. Over the course of his career, Michael has also demonstrated a collaborative approach to management that has galvanized global organizations to lead in digital marketing and technology. We are confident that Michael will bring a valuable perspective to drive Criteo's strategy forward, further enhancing our commerce and retail media leadership, and building on our strong momentum thanks to Megan's critical contributions and the dedication of the entire team."

Komasinski brings over two decades of experience in AdTech and building brand and retail relationships globally. He has consistently demonstrated the ability to achieve exceptional results at global organizations, leveraging technology-driven strategies to drive profitable growth while cultivating an inclusive work environment. He currently serves as CEO of the Americas, President of Global Data & Technology, and member of the Group Executive Management team at dentsu, one of the largest global advertising holding companies. He joined dentsu through its acquisition of Merkle in 2016 and led both the EMEA and Americas regions before becoming Global CEO of Merkle in 2021. At dentsu, Komasinski led the technological transformation of its product suite during a time of rapid innovation. Those efforts included embedding AI across dentsu's products and platforms to enhance value for clients and defining dentsu's client-facing data-driven technology strategy, which resulted in significant enterprise client wins. He also has vast retail media expertise, having grown Merkle's retail media consulting practice and combining it with dentsu's leading media buy-side capabilities.

"Criteo's transformation into a global commerce media powerhouse and AdTech leader has been inspiring, and I am excited and energized to serve as the company's next CEO and build on this momentum," said Komasinski. "There are massive growth opportunities in media today with new advancements in AI and a global rise in ecommerce, which are driving hyper-personalized consumer touchpoints across more content and devices than ever before. I'm thrilled to be partnering with Criteo's talented team, who has built incredible assets in AI over the years, to deliver compelling commerce solutions for our clients and drive shareholder value."

Prior to joining dentsu, Komasinski was responsible at Merkle for overseeing a staff of more than 14,000 employees in over 50 locations throughout the Americas, EMEA, and APAC. He previously served in leadership positions at Razorfish, Schawk Retail Marketing, The Nielsen Company, and A.T. Kearney. Komasinski is a board member of the Ad Council and serves on the client advisory boards of Meta and Microsoft. He holds a Bachelor of Science degree in Engineering and Philosophy from Vanderbilt University and an MBA degree from Indiana University's Kelley School of Business.

About Criteo

Criteo (NASDAQ: CRTO) is the global commerce media company that enables marketers and media owners to drive better commerce outcomes. Its industry leading Commerce Media Platform connects thousands of marketers and media owners to deliver richer consumer experiences from product discovery to purchase. By powering trusted and impactful advertising, Criteo supports an open internet that encourages discovery, innovation, and choice. For more information, please visit www.criteo.com.

Contacts

Criteo Investor Relations
Melanie Dambre, [email protected]

Criteo Public Relations
Jessica Meyers, [email protected]

OR

Camilla Scassellati-Sforzolini, Warren Rizzi
FGS Global
[email protected]

SOURCE Criteo S.A.

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.